IRIS
DELLA CORTE, Carminia Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.473
AS - Asia 2.553
NA - Nord America 2.064
SA - Sud America 362
AF - Africa 31
OC - Oceania 4
Totale 8.487
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.994
RU - Federazione Russa 1.543
SG - Singapore 982
IE - Irlanda 626
IT - Italia 554
HK - Hong Kong 498
CN - Cina 478
BR - Brasile 313
DE - Germania 216
KR - Corea 178
VN - Vietnam 138
GB - Regno Unito 124
FR - Francia 103
IN - India 78
UA - Ucraina 74
JP - Giappone 69
FI - Finlandia 61
CA - Canada 37
AT - Austria 35
GR - Grecia 34
NL - Olanda 25
TR - Turchia 25
BD - Bangladesh 20
MX - Messico 19
SE - Svezia 19
PK - Pakistan 18
AR - Argentina 16
ID - Indonesia 16
CZ - Repubblica Ceca 10
EC - Ecuador 10
IQ - Iraq 10
PL - Polonia 10
ZA - Sudafrica 10
BE - Belgio 9
CL - Cile 9
ES - Italia 8
AE - Emirati Arabi Uniti 7
PY - Paraguay 7
AZ - Azerbaigian 6
DO - Repubblica Dominicana 5
MA - Marocco 5
CO - Colombia 4
HU - Ungheria 4
TN - Tunisia 4
CH - Svizzera 3
IR - Iran 3
KE - Kenya 3
KG - Kirghizistan 3
LT - Lituania 3
PT - Portogallo 3
SA - Arabia Saudita 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AM - Armenia 2
AU - Australia 2
EG - Egitto 2
HR - Croazia 2
IL - Israele 2
JO - Giordania 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
SV - El Salvador 2
TW - Taiwan 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
MY - Malesia 1
PS - Palestinian Territory 1
RO - Romania 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
VE - Venezuela 1
Totale 8.487
Salva come PNG Salva come JPEG
Città #
Dublin 618
Moscow 499
Hong Kong 497
Singapore 442
Santa Clara 364
Chandler 285
Seoul 178
Naples 154
Jacksonville 138
Dallas 108
Beijing 100
Hefei 92
Ashburn 86
Munich 86
New York 82
Princeton 71
Roxbury 70
Bremen 60
The Dalles 59
Bengaluru 54
Ho Chi Minh City 50
Medford 36
Turku 36
Cambridge 35
Caserta 35
São Paulo 28
Hanoi 26
Nuremberg 25
Wilmington 24
Los Angeles 22
Dong Ket 20
Boardman 19
Elora 18
Vienna 18
Napoli 17
Des Moines 16
Ann Arbor 15
Rome 13
Milan 12
Afragola 11
Amsterdam 11
Brooklyn 10
Council Bluffs 10
Falkenstein 10
Belo Horizonte 9
Brussels 9
Columbus 9
Da Nang 9
Ercolano 9
Aversa 8
Brno 8
Lappeenranta 8
London 8
Piscataway 8
Pozzuoli 8
Rio de Janeiro 8
Tokyo 8
Dhaka 7
Florence 7
Guangzhou 7
Istanbul 7
Jakarta 7
San Francisco 7
Toronto 7
Warsaw 7
Baku 6
Boston 6
Brasília 6
Phoenix 6
Rawalpindi 6
San Mateo 6
Shanghai 6
Venice 6
Viterbo 6
Woodbridge 6
Bahawalpur 5
Battipaglia 5
Campinas 5
Haiphong 5
Helsinki 5
Nanjing 5
Porto Alegre 5
Somma Vesuviana 5
Sorocaba 5
Acerra 4
Anantapur 4
Asunción 4
Chicago 4
Giugliano in Campania 4
Guarulhos 4
Guayaquil 4
Manchester 4
Mountain View 4
Norwalk 4
Paris 4
Santiago 4
Stockholm 4
Zhengzhou 4
Athens 3
Atlanta 3
Totale 4.892
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 146
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 142
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 137
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 131
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 121
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 116
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 111
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 111
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 108
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 107
Immunotherapy for head and neck cancer: Present and future 101
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 101
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 98
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 97
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 97
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 97
Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign 96
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 95
Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy 95
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 95
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 93
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 92
Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. 91
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 91
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 91
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs 91
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 91
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 90
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 90
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 89
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis 88
AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors 88
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 88
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 87
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 86
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 86
A Critical Issue in Lung Cancer Cytology and Small Biopsies: DNA and RNA Extraction from Archival Stained Slides for Biomarker Detection through Real Time PCR and NGS-The Experience in Pathological Anatomy Unit 86
Diagnosis of malignant pleural disease: Ultrasound as "a detective probe" 84
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era 84
The use of ultrasound in the evaluation of postoperative pneumothorax and lung re-expansion in patients after lung resection 84
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 83
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 83
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 83
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 83
Discovery of N-Substituted-2-Oxoindolin Benzoylhydrazines as c-MET/SMO Modulators in EGFRi-Resistant Non-Small Cell Lung Cancer 82
Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyond 81
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 80
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 80
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 79
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 79
Mechanisms of resistance to EGFR-targeted drugs: lung cancer 79
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 78
Ventilation challenge in rigid bronchoscopy: Laser tube as an alternative management in patients with lung cancer and central airway obstruction 78
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 76
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 76
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines 76
Translational insights and new therapeutic perspectives in head and neck tumors 76
Primary pleural squamous cell carcinoma: A diagnostic challenge 75
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 74
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer 74
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 74
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 73
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti- tumor immune response in peripheral immune cells of NSCLC patients 72
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 72
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC 70
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. 69
Kisspeptin and cancer: Molecular interaction, biological functions, and future perspectives 69
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems 68
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 68
ROLE OF THE HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO ANTI-EGFR TYROSINE KINASE INHIBITORS IN NON SMALL CELL LUNG CANCER 68
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy 68
Role of HGF-MET signaling in primary and acquired resistance to targeted therapies in cancer 68
Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors 68
Implication of the Hedgehog pathway in hepatocellular carcinoma. 67
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 67
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 65
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy 64
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 63
Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study 61
Evading the STING: LKB1 loss leads to STING silencing and immune escape in KRAS-mutant lung cancers 61
Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR 60
Early use of steroids affects immune cells and impairs immunotherapy efficacy 60
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 60
Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma 60
PATZ1 in Non-Small Cell Lung Cancer: A New Biomarker That Negatively Correlates with PD-L1 Expression and Suppresses the Malignant Phenotype 59
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer 59
Unleashing precision: A review of targeted approaches in pleural mesothelioma 59
ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer 58
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 56
Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients 56
Role and targeting of anaplastic lymphoma kinase in cancer 55
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype 55
The role of coronary artery calcification score in lung cancer patients 54
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 53
Rescue Surgery for Advanced Stage Lung Cancer: A Systematic Review 53
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy 53
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review 52
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 52
Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy? 52
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 52
Totale 8.020
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.162
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.162
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021158 0 0 0 0 0 6 39 19 15 16 37 26
2021/2022501 9 7 9 9 110 10 44 18 26 37 67 155
2022/20231.193 114 30 25 114 127 92 12 58 558 13 29 21
2023/2024612 61 25 24 30 170 80 20 24 11 17 53 97
2024/20252.183 26 51 22 56 307 277 267 199 333 318 166 161
2025/20263.571 396 455 439 360 774 1.147 0 0 0 0 0 0
Totale 8.752